Seroepidemiological Survey of the Antibody for Severe Acute Respiratory Syndrome Coronavirus 2 with Neutralizing Activity at Hospitals: A Cross-sectional Study in Hyogo Prefecture, Japan

DOI HANDLE Web Site 被引用文献1件 オープンアクセス
  • Furukawa Koichi
    Division of Clinical Virology, Center for Infectious Disease, Kobe University Graduate School of Medicine, Kobe, Japan
  • Arii Jun
    Division of Clinical Virology, Center for Infectious Disease, Kobe University Graduate School of Medicine, Kobe, Japan
  • Nishimura Mitsuhiro
    Division of Clinical Virology, Center for Infectious Disease, Kobe University Graduate School of Medicine, Kobe, Japan
  • Tjan Lidya Handayani
    Division of Clinical Virology, Center for Infectious Disease, Kobe University Graduate School of Medicine, Kobe, Japan
  • Lystia Poetranto Anna
    Division of Clinical Virology, Center for Infectious Disease, Kobe University Graduate School of Medicine, Kobe, Japan
  • Ren Zhenxiao
    Division of Clinical Virology, Center for Infectious Disease, Kobe University Graduate School of Medicine, Kobe, Japan
  • Aktar Salma
    Division of Clinical Virology, Center for Infectious Disease, Kobe University Graduate School of Medicine, Kobe, Japan
  • Huang Jing Rin
    Division of Clinical Virology, Center for Infectious Disease, Kobe University Graduate School of Medicine, Kobe, Japan
  • Sutandhio Silvia
    Division of Clinical Virology, Center for Infectious Disease, Kobe University Graduate School of Medicine, Kobe, Japan
  • Kurahashi Yukiya
    Division of Clinical Virology, Center for Infectious Disease, Kobe University Graduate School of Medicine, Kobe, Japan
  • Nishino Arisa
    Division of Clinical Virology, Center for Infectious Disease, Kobe University Graduate School of Medicine, Kobe, Japan
  • Shigekuni Shiho
    Division of Clinical Virology, Center for Infectious Disease, Kobe University Graduate School of Medicine, Kobe, Japan
  • Takeda Yuichiro
    Division of Clinical Virology, Center for Infectious Disease, Kobe University Graduate School of Medicine, Kobe, Japan
  • Uto Kenichi
    Department of Clinical Laboratory, Kobe University Hospital, Kobe, Japan
  • Matsui Keiji
    Department of Clinical Laboratory, Kobe University Hospital, Kobe, Japan
  • Sato Itsuko
    Department of Clinical Laboratory, Kobe University Hospital, Kobe, Japan
  • Inui Yoshiaki
    Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Japan
  • Endo Kazuo
    Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan
  • Kosaka Yoshiyuki
    Hyogo Prefectural Kobe Children's Hospital, Kobe, Japan
  • Oota Toshiaki
    Hyogo Prefecture Health Promotion Association, Kobe, Japan
  • Saegusa Jun
    Department of Clinical Laboratory, Kobe University Hospital, Kobe, Japan
  • Mori Yasuko
    Division of Clinical Virology, Center for Infectious Disease, Kobe University Graduate School of Medicine, Kobe, Japan

この論文をさがす

抄録

<p>Introduction: The coronavirus disease 2019 (COVID-19) pandemic is spreading rapidly all over the world. The Japanese government lifted the state of emergency, announced in April 2020, on May 25, but there are still sporadic clusters. Asymptomatic patients who can transmit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cause some of these clusters. It is thus urgent to investigate the seroprevalence of antibodies against SARS-CoV-2 and their neutralizing activity. We conducted a cross-sectional study of >10,000 samples at hospitals in Hyogo Prefecture, Japan.</p><p>Methods: Between August 6 and October 1, 2020, we collected samples of residual blood from the patients who visited or were admitted to five hospitals and a foundation in Hyogo. We tested the samples for antibodies against SARS-CoV-2 by electrochemiluminescence immunoassay (ECLIA) and chemiluminescent enzyme immunoassay (CLEIA). Sera that were positive by ECLIA or CLEIA were analyzed by an immunochromatographic (IC) test and neutralizing activity assay.</p><p>Results: We tested 10,377 samples from patients aged between 0 and 99 years old; 27 cases (0.26%) were positive on the ECLIA, and 51 cases (0.49%) were positive on CLEIA. In the 14 cases that tested positive on both ECLIA and CLEIA, the positive rates on the IC test and for neutralizing activity were high (85% and 92%, respectively). In 50 cases (0.48%) that were positive by either ECLIA or CLEIA, the corresponding rates were low (20% and 6%, respectively). The positive rate of neutralizing antibody was 0.15%.</p><p>Conclusions: These results indicate that most Hyogo Prefecture residents still do not have antibodies and should avoid the risk of incurring a SARS-CoV-2 infection. Two or more antibody tests should be required for seroepidemiological studies of the antibody for SARS-CoV-2, and a neutralizing activity assay is also essential.</p>

収録刊行物

  • JMA Journal

    JMA Journal 4 (1), 41-49, 2021-01-29

    公益社団法人 日本医師会 / 日本医学会

被引用文献 (1)*注記

もっと見る

関連プロジェクト

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ